Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BerlexYasmin Reps Likely To Promote Anti-Fluid, Androgen Effects

Executive Summary

Sales reps will likely detail Yasmin by promoting its anti-fluid-retention and anti-androgen effects when the oral contraceptive becomes available in mid-June.
Advertisement

Related Content

Berlex Yasmin 20 NDA Filing For Lower Estrogen Dose Slated For Q4
Berlex Yasmin 20 NDA Filing For Lower Estrogen Dose Slated For Q4
Advertisement
UsernamePublicRestriction

Register

PS037851

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel